Clinical Trial Update: A 35 Day Study to Investigate the Effects of GSK1521498 on Bodyweight in Obese Subjects With Over-Eating Behaviours. [Phase 2]

View source ↗

Summary

A completed Phase 2 trial investigating the effect of the investigational compound GSK1521498 on bodyweight in obese adults with overeating behaviours. The upda…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• GSK1521498 (GSK1521498)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Obesity | Phase 2 | Status: COMPLETED